News & Media

News & Media

News Releases

Company announcements

  • Interlude Biopharma Launches at the International Celiac Disease Symposium and Announces Prevention-Focused Phase 3 Clinical Trial

    First celiac prevention study expected to start in the first quarter of 2027.

    Read the release on PR Newswire
  • Interlude at ICDS 2026, Melbourne

    ICDS 2026 website
Media Resources

Media contact

Events & Presentations

Upcoming events

Nov 202617–20

International Celiac Disease Symposium (ICDS 2026)

Date: November 17–20, 2026  ·  Location: Melbourne, Australia

Interlude Biopharma will be featured in the digital conference program for ICDS 2026, an international gathering of researchers, clinicians, and industry leaders focused on advancing celiac disease research, diagnosis, and treatment.

Interlude is advancing larazotide acetate, an investigational, first-in-class oral tight junction regulator designed to protect the intestinal barrier against gluten-induced injury in people with celiac disease, as an adjunct to the gluten-free diet.

Learn more about ICDS 2026